Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

被引:210
作者
Barosi, Giovanni [1 ,2 ]
Birgegard, Gunnar [3 ]
Finazzi, Guido [4 ]
Griesshammer, Martin [5 ]
Harrison, Claire [6 ]
Hasselbalch, Hans Carl [7 ]
Kiladjian, Jean-Jacques [8 ]
Lengfelder, Eva [9 ]
McMullin, Mary Frances [10 ]
Passamonti, Francesco [11 ]
Reilly, John T. [12 ]
Vannucchi, Alessandro M. [13 ]
Barbui, Tiziano [14 ]
机构
[1] Fdn Ist Ricovero & Cura Carattere Sci, Policlin San Matteo, Lab Epidemiol Clin, Clin Epidemiol Unit, I-27100 Pavia, Italy
[2] Fdn Ist Ricovero & Cura Carattere Sci, Policlin San Matteo, Lab Epidemiol Clin, Ctr Study Myelofibrosis, I-27100 Pavia, Italy
[3] Univ Uppsala Hosp, Dept Haematol, Uppsala, Sweden
[4] Osped Riuniti Bergamo, Div Transfus Med, I-24100 Bergamo, Italy
[5] Univ Hannover, Acad Hosp, Dept Hematol & Oncol, Johannes Wesling Med Ctr Minden, Minden, Germany
[6] Guys & St Thomas Natl Hlth Serv Fdn Trust, Dept Haematol, London, England
[7] Univ Copenhagen, Dept Hematol, L Herlev Hosp, Copenhagen, Denmark
[8] Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[9] Heidelberg Univ, Dept Med 3, Fac Med Mannheim, Heidelberg, Germany
[10] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[11] Univ Pavia, Fdn Ist Ricovero & Cura Carattere Sci, Policlin San Matteo, I-27100 Pavia, Italy
[12] Royal Hallamshire Hosp, Mol Haematol Unit, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England
[13] Univ Florence, Unita Funz Ematol, Dipartimento Area Crit Med Chirurg, Florence, Italy
[14] Osped Riuniti Bergamo, Div Hematol, I-24100 Bergamo, Italy
关键词
MYELOPROLIFERATIVE DISORDERS; MPL MUTATIONS; ANAGRELIDE; EFFICACY; THERAPY; MYELOFIBROSIS; HYDROXYUREA; HEMATOCRIT; GUIDELINES; SAFETY;
D O I
10.1182/blood-2008-09-176818
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
European experts were convened to develop a definition of response to treatment in polycythemia vera (PV) and essential thrombocythemia (ET). Clinico-hematologic (CH), molecular, and histologic response categories were selected. In ET, CH complete response (CR) was: platelet count less than or equal to 400 x 10(9)/L, no disease-related symptoms, normal spleen size, and white blood cell count less than or equal to 10 x 10(9)/L. Platelet count less than or equal to 600 x 10(9)/L or a decrease greater than 50% was partial response (PR). In PV, CH-CR was: hematocrit less than 45% without phlebotomy, platelet count less than or equal to 400 x 10(9)/L, white blood cell count less than or equal to 10 x 10(9)/L, and no disease-related symptoms. A hematocrit less than 45% without phlebotomy or response in 3 or more of the other criteria was defined as PR. In both ET and in PV, molecular CR was a reduction of any molecular abnormality to undetectable levels. Molecular PR was defined as a reduction more than or equal to 50% in patients with less than 50% mutant allele burden, or a reduction more than or equal to 25% in patients with more than 50% mutant allele burden. Bone marrow histologic response in ET was judged on megakaryocyte hyperplasia while on cellularity and reticulin fibrosis in PV. The combined use of these response definitions should help standardize the design and reporting of clinical studies. (Blood. 2009;113:48294833)
引用
收藏
页码:4829 / 4833
页数:5
相关论文
共 29 条
[1]
Barbui T, 2004, HAEMATOLOGICA, V89, P215
[2]
Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk [J].
Barbui, Tiziano ;
Finazzi, Guido .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (04) :321-329
[3]
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) [J].
Barosi, G ;
Bordessoule, D ;
Briere, J ;
Cervantes, F ;
Demory, JL ;
Dupriez, B ;
Gisslinger, H ;
Griesshammer, M ;
Hasselbalch, H ;
Kusec, R ;
Le Bousse-Kerdiles, MC ;
Liberato, NL ;
Marchetti, M ;
Reilly, JT ;
Thiele, J .
BLOOD, 2005, 106 (08) :2849-2853
[4]
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort [J].
Beer, Philip A. ;
Campbell, Peter J. ;
Scott, Linda M. ;
Bench, Anthony J. ;
Erber, Wendy N. ;
Bareford, David ;
Wilkins, Bridget S. ;
Reilly, John T. ;
Hasselbalch, Hans C. ;
Bowman, Richard ;
Wheatley, Keith ;
Buck, Georgina ;
Harrison, Claire N. ;
Green, Anthony R. .
BLOOD, 2008, 112 (01) :141-149
[5]
Delbecq A.L., 1975, GROUP TECHNIQUES PRO
[6]
The haematocrit and platelet target in polycythemia vera [J].
Di Nisio, Marcello ;
Barbui, Tiziano ;
Di Gennaro, Leonardo ;
Borrelli, Giovanna ;
Finazzi, Guido ;
Landolfi, Raffaele ;
Leone, Giuseppe ;
Marfisi, RosaMaria ;
Porreca, Ettore ;
Ruggeri, Marco ;
Rutjes, Anne W. S. ;
Tognoni, Gianni ;
Vannucchi, Alessandro M. ;
Marchioli, Roberto .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (02) :249-259
[7]
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].
Harrison, CN ;
Campbell, PJ ;
Buck, G ;
Wheatley, K ;
East, CL ;
Bareford, D ;
Wilkins, BS ;
van der Walt, JD ;
Reilly, JT ;
Grigg, AP ;
Revell, P ;
Woodcock, BE ;
Green, AR ;
Pearson, TC ;
Conneally, E ;
Crawley, C ;
Cross, NCP ;
Hall, G ;
Hunt, B ;
Lucas, G ;
Ludlam, C ;
McMullin, MF ;
Oscier, D ;
Radia, D ;
Reilly, JT ;
Robinson, G ;
Culligan, DJ ;
Tighe, J ;
Watson, HG ;
Warren, AJ ;
Awaad, MO ;
Obeid, D ;
Cuthbert, RJG ;
Kyle, A ;
Chan-Lam, D ;
Paul, B ;
Cuthbert, RJG ;
McMullin, MF ;
Morris, TCM ;
Johnson, RJ ;
Fegan, C ;
Milligan, DW ;
Galloway, MJ ;
Williamson, PJ ;
Newton, LJ ;
Williams, AT ;
Abboudi, Z ;
Ryan, K ;
Lush, R ;
Blundell, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45
[8]
PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders -: Final result of a phase 2 study [J].
Jabbour, Elias ;
Kantarjian, Hagop ;
Cortes, Jorge ;
Thomas, Deborah ;
Garcia-Manero, Guillermo ;
Ferrajoli, Alessandra ;
Faderl, Stefan ;
Richie, Mary Ann ;
Beran, Miloslav ;
Giles, Francis ;
Verstovsek, Srdan .
CANCER, 2007, 110 (09) :2012-2018
[9]
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera [J].
Kiladjian, Jean-Jacques ;
Cassinat, Bruno ;
Chevret, Sylvie ;
Turlure, Pascal ;
Cambier, Nathalie ;
Roussel, Murielle ;
Bellucci, Sylvia ;
Grandchamp, Bernard ;
Chomienne, Christine ;
Fenaux, Pierre .
BLOOD, 2008, 112 (08) :3065-3072
[10]
Efficacy and safety of low-dose aspirin in polycythemia vera [J].
Landolfi, R ;
Marchioli, R ;
Kutti, J ;
Gisslinger, H ;
Tognoni, G ;
Patrono, C ;
Barbui, T ;
Landolfi, R ;
Marchioli, R ;
Kutti, J ;
Gisslinger, H ;
Tognoni, G ;
Patrono, C ;
Barbui, T ;
Gisslinger, H ;
Barbui, T ;
Finazzi, G ;
Pusterla, S ;
Falanga, A ;
Galli, M ;
Kutti, J ;
Wadenvik, H ;
Gastl, G ;
Ludescher, C ;
Lutz, D ;
Girschikofsky, M ;
Michlmayr, G ;
Rechberger, E ;
Niessner, H ;
Ivansich, E ;
Rain, JD ;
Chommienne-Thomas, C ;
Hehlmann, R ;
Engelich, G ;
Kohne, E ;
Kramer, A ;
Christakis, JI ;
Papaioannou, M ;
Gerotziafas, G ;
O'Donnell, R ;
Bennett, M ;
Lugassy, G ;
Ellis, M ;
Eldor, A ;
Naparstek, E ;
Marilus, R ;
Leoni, P ;
Rupoli, S ;
Scortechini, AR ;
Agostini, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (02) :114-124